Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · November 14, 2012

Plasma 25-Hydroxyvitamin D3 and Bladder Cancer Risk According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study

Journal of the National Cancer Institute

 

Additional Info

Journal of the National Cancer Institute
Plasma 25-Hydroxyvitamin D3 and Bladder Cancer Risk According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study
J. Natl. Cancer Inst 2012 Oct 29;[EPub Ahead of Print], AF Amaral, M Méndez-Pertuz, A Muñoz, DT Silverman, Y Allory, M Kogevinas, J Lloreta, N Rothman, A Carrato, Del Rivas, FX Real, N Malats

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading